Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating income | -$6.90M | -$5.74M | -$3.96M | -$2.61M | -$3.49M | -$1.81M | -$1.99M | -$1.78M | -$1.54M | -$57.3M |
| Net income | -$9.41M | -$7.87M | -$7.04M | -$5.76M | -$4.74M | -$2.03M | -$2.66M | -$2.66M | -$1.82M | -$58.9M |
| EPS (diluted) | -$4.83 | -$2.24 | -$178.75 | -$10.97 | -$192.45 | -$0.80 | -$49.23 | -$1.80 | -$1,420.53 | -$14.85 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$4.50M | -$2.05M | -$2.18M | -$2.06M | -$1.85M | -$1.15M | -$1.44M | -$1.11M | -$935K | -$405K |
| Capital expenditures | $9.88K | — | — | $2.87K | — | — | — | — | — | — |
| Free cash flow | -$4.51M | — | — | -$2.06M | — | — | — | — | — | — |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | — | — | — | — | $67.0K | $2.25K | $4.07K | — | — | — |
| Total assets | $379K | $95.1K | $71.4K | $102K | $98.5K | $13.1K | $81.7K | $60.3K | $72.4K | $19.6M |
| Total liabilities | — | — | — | $4.40M | $3.74M | $3.08M | $3.11M | $3.18M | $3.85M | $5.73M |
| Long-term debt | $1.20M | $3.48M | $4.70M | $1.66M | $1.56M | $625K | $926K | $391K | $399K | $538K |
| Shareholders' equity | -$2.57M | -$5.44M | -$6.75M | -$4.30M | -$3.64M | -$3.07M | -$3.02M | -$3.12M | -$3.78M | $13.9M |
| Retained earnings | -$30.4M | -$38.2M | -$45.3M | -$51.0M | -$55.8M | -$58.2M | -$61.6M | -$64.7M | -$66.7M | -$126M |
| Shares (wtd avg diluted) | 2.91M | 4.55M | 92.8B | 968K | 258K | 3.03M | 68.2B | 1.74M | 1.42B | 3.97M |
Every figure is extracted from Propanc Biopharma, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.